- Home
- VNDA vs JPI Comparison
VNDA vs JPI Comparison
Compare VNDA & JPI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VNDA
- JPI
- Stock Information
- Founded
- VNDA 2002
- JPI 2012
- Country
- VNDA United States
- JPI United States
- Employees
- VNDA N/A
- JPI N/A
- Industry
- VNDA Biotechnology: Pharmaceutical Preparations
- JPI Finance Companies
- Sector
- VNDA Health Care
- JPI Finance
- Exchange
- VNDA Nasdaq
- JPI Nasdaq
- Market Cap
- VNDA 282.8M
- JPI 278.6M
- IPO Year
- VNDA 2006
- JPI N/A
- Fundamental
- Price
- VNDA $5.07
- JPI $19.47
- Analyst Decision
- VNDA Strong Buy
- JPI
- Analyst Count
- VNDA 2
- JPI 0
- Target Price
- VNDA $16.50
- JPI N/A
- AVG Volume (30 Days)
- VNDA 778.6K
- JPI 54.7K
- Earning Date
- VNDA 05-07-2025
- JPI 01-01-0001
- Dividend Yield
- VNDA N/A
- JPI 6.15%
- EPS Growth
- VNDA N/A
- JPI N/A
- EPS
- VNDA N/A
- JPI N/A
- Revenue
- VNDA $198,772,000.00
- JPI N/A
- Revenue This Year
- VNDA $14.36
- JPI N/A
- Revenue Next Year
- VNDA $44.53
- JPI N/A
- P/E Ratio
- VNDA N/A
- JPI N/A
- Revenue Growth
- VNDA 3.18
- JPI N/A
- 52 Week Low
- VNDA $3.71
- JPI $16.02
- 52 Week High
- VNDA $6.75
- JPI $19.12
- Technical
- Relative Strength Index (RSI)
- VNDA 58.96
- JPI 28.06
- Support Level
- VNDA $4.84
- JPI $19.78
- Resistance Level
- VNDA $5.07
- JPI $19.79
- Average True Range (ATR)
- VNDA 0.23
- JPI 0.21
- MACD
- VNDA 0.02
- JPI -0.06
- Stochastic Oscillator
- VNDA 70.63
- JPI 0.76
About VNDA Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.
About JPI Nuveen Preferred and Income Term Fund of Beneficial Interest
Nuveen Preferred and Income Term Fund is a closed-end management investment company. Its investment objective is to provide a high level of current income and total return. The company's products include mutual funds, closed-end funds, Exchange-traded funds, Multi-asset model portfolios, and others.